
Craig D. Ricci
Examiner (ID: 10445, Phone: (571)270-5864 , Office: P/1628 )
| Most Active Art Unit | 1628 |
| Art Unit(s) | 1611, 1628, 1614 |
| Total Applications | 1547 |
| Issued Applications | 760 |
| Pending Applications | 153 |
| Abandoned Applications | 681 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17865423
[patent_doc_number] => 20220288158
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => NOVEL ENTERIC COMBINATION THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/829194
[patent_app_country] => US
[patent_app_date] => 2022-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4435
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17829194
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/829194 | NOVEL ENTERIC COMBINATION THERAPY | May 30, 2022 | Abandoned |
Array
(
[id] => 19120092
[patent_doc_number] => 11964053
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-23
[patent_title] => Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals
[patent_app_type] => utility
[patent_app_number] => 17/828412
[patent_app_country] => US
[patent_app_date] => 2022-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6090
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 180
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17828412
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/828412 | Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals | May 30, 2022 | Issued |
Array
(
[id] => 17828298
[patent_doc_number] => 20220265602
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT
[patent_app_type] => utility
[patent_app_number] => 17/744185
[patent_app_country] => US
[patent_app_date] => 2022-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12145
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17744185
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/744185 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | May 12, 2022 | Issued |
Array
(
[id] => 17837700
[patent_doc_number] => 20220275005
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => HETEROCYCLIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/737656
[patent_app_country] => US
[patent_app_date] => 2022-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14791
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17737656
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/737656 | HETEROCYCLIC COMPOUNDS | May 4, 2022 | Abandoned |
Array
(
[id] => 17828236
[patent_doc_number] => 20220265540
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => COMPOSITION COMPRISING ALKYLCELLULOSE, INCOMPATIBLE HYDROCARBON AND SILICONE OILS AND METHOD EMPLOYING IT
[patent_app_type] => utility
[patent_app_number] => 17/735753
[patent_app_country] => US
[patent_app_date] => 2022-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18447
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17735753
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/735753 | COMPOSITION COMPRISING ALKYLCELLULOSE, INCOMPATIBLE HYDROCARBON AND SILICONE OILS AND METHOD EMPLOYING IT | May 2, 2022 | Pending |
Array
(
[id] => 17790303
[patent_doc_number] => 20220249394
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => METHOD FOR SELECTIVELY KILLING PROTEIN AGGREGATE-CONTAINING CELLS, KIT THEREFOR, THERAPEUTIC DRUG FOR PROTEIN MISFOLDING DISEASES AND DRUG PRODUCT FOR REMOVING PROTEIN AGGREGATES FROM BLOOD PRODUCT
[patent_app_type] => utility
[patent_app_number] => 17/731942
[patent_app_country] => US
[patent_app_date] => 2022-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8432
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17731942
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/731942 | METHOD FOR SELECTIVELY KILLING PROTEIN AGGREGATE-CONTAINING CELLS, KIT THEREFOR, THERAPEUTIC DRUG FOR PROTEIN MISFOLDING DISEASES AND DRUG PRODUCT FOR REMOVING PROTEIN AGGREGATES FROM BLOOD PRODUCT | Apr 27, 2022 | Abandoned |
Array
(
[id] => 18932275
[patent_doc_number] => 11884681
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-30
[patent_title] => 3H,4H,5H,6H,7H-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as TRPA1 inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/719430
[patent_app_country] => US
[patent_app_date] => 2022-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11051
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17719430
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/719430 | 3H,4H,5H,6H,7H-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as TRPA1 inhibitors | Apr 12, 2022 | Issued |
Array
(
[id] => 17759908
[patent_doc_number] => 20220233520
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-28
[patent_title] => Increasing Drug Bioavailability In Naltrexone Therapy
[patent_app_type] => utility
[patent_app_number] => 17/717691
[patent_app_country] => US
[patent_app_date] => 2022-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13329
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17717691
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/717691 | Increasing Drug Bioavailability In Naltrexone Therapy | Apr 10, 2022 | Pending |
Array
(
[id] => 18273714
[patent_doc_number] => 11612635
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-03-28
[patent_title] => Enteric combination therapy
[patent_app_type] => utility
[patent_app_number] => 17/715009
[patent_app_country] => US
[patent_app_date] => 2022-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4391
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17715009
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/715009 | Enteric combination therapy | Apr 5, 2022 | Issued |
Array
(
[id] => 18329168
[patent_doc_number] => 11634396
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-25
[patent_title] => Opioid receptor modulators
[patent_app_type] => utility
[patent_app_number] => 17/714030
[patent_app_country] => US
[patent_app_date] => 2022-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43029
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17714030
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/714030 | Opioid receptor modulators | Apr 4, 2022 | Issued |
Array
(
[id] => 19248654
[patent_doc_number] => 20240199641
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => QUINAZOLINE-4(3H)-ONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2
[patent_app_type] => utility
[patent_app_number] => 18/553406
[patent_app_country] => US
[patent_app_date] => 2022-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15258
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 224
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18553406
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/553406 | QUINAZOLINE-4(3H)-ONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | Mar 31, 2022 | Pending |
Array
(
[id] => 19233673
[patent_doc_number] => 20240190865
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/280096
[patent_app_country] => US
[patent_app_date] => 2022-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57069
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18280096
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/280096 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | Mar 2, 2022 | Pending |
Array
(
[id] => 19232113
[patent_doc_number] => 20240189304
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => BET PROTEIN INHIBITORS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/548844
[patent_app_country] => US
[patent_app_date] => 2022-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13614
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18548844
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/548844 | BET PROTEIN INHIBITORS AND USE THEREOF | Mar 1, 2022 | Pending |
Array
(
[id] => 17655506
[patent_doc_number] => 20220175971
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => DYE ENHANCED VISUALIZATION OF CATARACT SURGERY
[patent_app_type] => utility
[patent_app_number] => 17/682711
[patent_app_country] => US
[patent_app_date] => 2022-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6499
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17682711
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/682711 | DYE ENHANCED VISUALIZATION OF CATARACT SURGERY | Feb 27, 2022 | Abandoned |
Array
(
[id] => 18270459
[patent_doc_number] => 20230091701
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => METHODS OF TREATING HEPATIC ENCEPHALOPATHY
[patent_app_type] => utility
[patent_app_number] => 17/682624
[patent_app_country] => US
[patent_app_date] => 2022-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43321
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17682624
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/682624 | Methods of treating hepatic encephalopathy | Feb 27, 2022 | Issued |
Array
(
[id] => 18404573
[patent_doc_number] => 20230165924
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-01
[patent_title] => Herbal Formulation for the Prevention and Management of COVID-19 by Regulating Immunomodulatory Properties
[patent_app_type] => utility
[patent_app_number] => 17/681368
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4824
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17681368
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/681368 | Herbal Formulation for the Prevention and Management of COVID-19 by Regulating Immunomodulatory Properties | Feb 24, 2022 | Abandoned |
Array
(
[id] => 18034535
[patent_doc_number] => 20220378750
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/680782
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17122
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680782
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/680782 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | Feb 24, 2022 | Abandoned |
Array
(
[id] => 17655554
[patent_doc_number] => 20220176019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => POROUS POLYMER SCAFFOLD AND METHODS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/679796
[patent_app_country] => US
[patent_app_date] => 2022-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4921
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17679796
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/679796 | POROUS POLYMER SCAFFOLD AND METHODS THEREOF | Feb 23, 2022 | Abandoned |
Array
(
[id] => 19140391
[patent_doc_number] => 20240139170
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => TOPICAL FORMULATIONS OF A JAK 1/3 INHIBITOR AND METHODS OF USE THEREOF FOR TREATMENT OF ATOPIC DERMATITIS AND OTHER SKIN CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 18/277886
[patent_app_country] => US
[patent_app_date] => 2022-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15631
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18277886
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/277886 | TOPICAL FORMULATIONS OF A JAK 1/3 INHIBITOR AND METHODS OF USE THEREOF FOR TREATMENT OF ATOPIC DERMATITIS AND OTHER SKIN CONDITIONS | Feb 17, 2022 | Pending |
Array
(
[id] => 17640516
[patent_doc_number] => 20220168254
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => PARENTERAL NUTRITION FORMULATION WITH OPTIMIZED AMINO ACID AND GLUCOSE CONTENT
[patent_app_type] => utility
[patent_app_number] => 17/670728
[patent_app_country] => US
[patent_app_date] => 2022-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10216
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17670728
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/670728 | PARENTERAL NUTRITION FORMULATION WITH OPTIMIZED AMINO ACID AND GLUCOSE CONTENT | Feb 13, 2022 | Pending |